Zivo Bioscience, Inc. is a research and development company operating in the biotech and agtech sectors with a focus on proprietary algal and bacterial strains. The company develops bioactive extracts and whole algal biomass for applications in human and animal health. Its core activities involve identifying therapeutic compounds from algal cultures and scaling commercial production of nutritional algae products.
Zivo Bioscience generates revenue through the development and…
Zivo Bioscience, Inc. is a research and development company operating in the biotech and agtech sectors with a focus on proprietary algal and bacterial strains. The company develops bioactive extracts and whole algal biomass for applications in human and animal health. Its core activities involve identifying therapeutic compounds from algal cultures and scaling commercial production of nutritional algae products.
Zivo Bioscience generates revenue through the development and potential licensing of therapeutic product candidates and the sale of its nutritional algae product Zivolife TM . The company pursues strategic partnerships in animal health for commercialization of its biotech innovations. Revenue from the agtech segment comes from commercial shipments of dried green algae powder sold under the Zivolife TM brand to consumers through online platforms.
The company operates through the following segments: Therapeutic (Biotech) and Nutrition (Agtech).
- Therapeutic (Biotech): This segment focuses on developing bioactive extracts, fractions, and molecules derived from proprietary algal culture for treating diseases in humans and animals. The lead product candidate targets coccidiosis in broiler chickens by modulating the immune system to combat parasitic infection. Additional indications under investigation include avian influenza, bovine mastitis, canine joint health, and human immune modulation.
- Nutrition (Agtech): This segment develops proprietary algal culture as a commercially viable nutritional product in dry, powdered form containing over 50% protein. The product is sold under the trademarked brand name Zivolife TM for human consumption as a food or food ingredient. Commercial production is conducted through a contract manufacturing agreement with Alimenta Algae SAC in Peru, with ZIVOLife LLC committed to purchasing the facility's output.
Zivo Bioscience operates in competitive industries including animal health, veterinary pharmaceuticals, and functional food ingredients. In the poultry gut health market, its non-antibiotic approach distinguishes it from conventional ionophore- and antibiotic-based treatments. The company leverages intellectual property and regulatory advantages such as self-affirmed GRAS status and USDA jurisdictional clarity to support its market position.
The company serves animal health producers, poultry farmers, and consumers seeking nutritional supplements. Specific customer partners include Grupo Alimenta for algae cultivation in Peru and ZWorldwide, Inc. for marketing and distribution of Zivolife TM in North America. The algal biomass is intended for use in human food, companion animal feed, and topical applications.